All Comments by Hiroshi Mori

  1. Estrogen blocks neurotoxic effects of beta-amyloid (1-42) and induces neurite extension on B103 cells.
  2. Cerebrovascular muscle atrophy is a feature of Alzheimer's disease.
  3. Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer's disease.
  4. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.
  5. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red.
  6. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease.
  7. Congo red inhibits proteoglycan and serum amyloid P binding to amyloid beta fibrils.
  8. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect?
  9. Apolipoprotein E polymorphism in patients with Alzheimer's disease, vascular dementia and ischemic cerebrovascular disease.
  10. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability.
  11. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies.
  12. Superoxide mediates the cell-death-enhancing action of presenilin-1 mutations.
  13. Presenilin 1 mutations linked to familial Alzheimer's disease increase the intracellular levels of amyloid beta-protein 1-42 and its N-terminally truncated variant(s) which are generated at distinct sites.
  14. Dementia with Lewy bodies.
  15. Amyloid plaques in Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex contain species of A beta similar to those found in the amyloid plaques of Alzheimer's disease and pathological aging.